| Product | Active Ingredients | Dosage form | Description | Launch date |
|---|---|---|---|---|
| Noxiall® | PEA + Commiphora Myrrha + Rosmarinus Officinalis + Piper Nigrum (of which Beta Caryophyllene) | Box of 20 tablets | Useful to contrast chronic and neuropathic pain | Jan 2017 |
| Partnena® | Magnesium + Parthenium + Andrographis Paniculata + Coenzyme Q10 + Vitamin B2 | Box of 28 tablets | Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states | Jan 2014 |
| Quetidia® | L-Theanine + Passiflora + Skullcap + Magnesium | Box of 30 tablets | Useful for the management of anxiety disorders | Sep 2014 |
| Quetidia® oral solution | L-Theanine + Passiflora + Skullcap + Magnesium | Oral solution. Bottle of 150 ml | Useful for the management of anxiety disorders | Sep 2017 |
| Seripnol® | L-Theanine + Magnolia + Ziziphus + Melatonin | Box of 28 sachets | Useful to promote relaxation and sleep | Mar 2012 |
| Seripnol® drops | L-Theanine + Melatonin + Magnolia + Ziziphus | Oral drops. Bottle of 30 ml | Useful to promote relaxation and sleep | Apr 2014 |
| Triadenor® | N-Acetyl-Cystein + S-Adenosyl -LMethionine + Folic Acid | Box of 16 tablets | Useful for the management of depressive disorders | Nov 2014 |
| UMP + Folic Acid + B12 | Uridine Monophosphate + Folic Acid + Vitamin B12 | Box of 20 and 40 film-coated tablets | Useful for the treatment of spinal syndromes, neuralgias and polyneuropathies | Jul 2018 |
| Vivifast® | Citicoline Cognizin® + Homotaurine + Vitamin E | Box of 20 tablets | Useful in the management of several types of cognitive disorders | Nov 2015 |
| Viviflux® | Homotaurine + DHA + Folic Acid | Box of 20 capsules | Indicated for stroke primary and secondary prevention and for cerebrovascular disorders | Sep 2011 |
| Vivimind® | Homotaurine | Box of 40 tablets | Intended to protect memory and cognitive functions in MCI patients | Nov 2010 |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.